SEC Form 4 · accession 0000899243-18-030864
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Israel Ruiz
Director
Period of report
Dec 11, 2018
Accepted (ET)
Dec 13, 2018 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001682852
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 11, 2018 | C | 4,559 | — | A | 4,559 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series G Preferred StockF1 | — | Dec 11, 2018 | C | 4,559 | D | — | — | Common Stock | 4,559 | 0 | D |
Explanation of responses
- F1The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date.